查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856292

抗体契约製造市场：下游－2025-2032年全球预测

Antibodies Contract Manufacturing Market by Downstream - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗体契约製造市场规模将达到 421.7 亿美元，复合年增长率为 11.19%。

主要市场统计数据
基准年 2024 180.4亿美元
预计年份：2025年 200.5亿美元
预测年份：2032年 421.7亿美元
复合年增长率 (%) 11.19%

全面介绍抗体契约製造领域，重点在于供应链的复杂性、营运韧性、技术推动因素和相关人员的需求。

抗体契约製造领域正经历着营运高度复杂化的时期，这主要得益于技术进步、监管要求和不断变化的商业性需求。本书将读者带入一个快速专业化的行业，在这个行业中，製造商和客户都将品质的稳定性、可扩展的工作流程和可重复的供应链放在首位。随着治疗方式的多样化和研发週期的缩短，受託製造製造商的价值日益凸显，不仅体现在其营运方面的专业知识，也体现在其整合上下游流程、打造稳健的端到端解决方案以降低转换风险的能力上。

分析抗体医药品受託製造模式下正在发生的变革性运作、技术和监管变化，这些变化正在重新定义品质预期和伙伴关係动态。

过去几年，抗体契约製造营运的预期发生了显着变化。自动化数位化已从先导计画扩展到核心流程控制，从而能够对关键品质属性进行严格监控，并确保研发和商业化阶段的资料连续性。同时，一次性技术和模组化设备缩短了部署时间，提高了灵活性，使服务供应商无需进行大规模设备维修即可服务多元化的客户群。

分析2025年美国新的关税措施将如何影响抗体生产相关人员的采购决策、供应链韧性和筹资策略。

美国将于2025年实施新的关税，无疑增加了抗体契约製造生态系统中采购和成本管理的复杂性。虽然这些关税不会改变科学研究工作流程，但会影响关键试剂、一次性组件和专用设备的采购成本，迫使生产商和赞助商重新评估其供应商选择标准和库存策略。为此，许多公司正在重新评估其近期筹资策略，优先考虑拥有多元化製造地和成熟跨境物流能力的供应商。

透过细分主导洞察，将下游层析法与上游生物製程要素连结起来，从而指导产能设计和製程整合选择的营运重点。

细緻的細項分析揭示了不同製程领域及其子组件如何驱动抗体生产价值链中的产能需求和投资重点。从下游角度来看，关键操作领域包括层析法纯化、过滤和离心、超过滤和渗滤，每个领域都有其特定的技术规格和设备需求。层析法纯化本身可细分为疏水交互作用层析法、离子交换层析法和蛋白A层析法，每种方法都会影响树脂处理、缓衝液消费量和一次性使用适用性，进而影响下游製程布局和运作成本。

区域分析重点阐述了在美洲、欧洲、中东和非洲以及亚太地区的策略布局如何影响监管合规能力规划和供应链弹性。

区域动态对合约研究公司和申办方的策略重点有显着影响。了解美洲、欧洲、中东和北非以及亚太地区之间的细微差别，对于有效的产能规划和监管应对至关重要。在美洲，商业规模的生产能力以及与主要生物製药中心的接近性通常有利于专案从研发阶段快速过渡到临床试验阶段，而监管机构则强调完善的文件记录和核准后监管，这可能会影响生产连续性计划。相反，在中东和北非地区，监管系统更为细分，需要灵活的品质系统和本地市场专业知识来管理跨司法管辖区的放行和检测。

对竞争格局进行全面分析，探讨卓越营运和策略伙伴关係如何决定差异化和服务可靠性。

主要企业的抗体医药品契约製造公司之间的竞争格局体现了技术深度、综合服务以及策略伙伴关係关係的融合。市场领导者透过提供从细胞系开发和製程优化到规模化生产和商业化支援的全面解决方案来脱颖而出，从而降低交接风险并加快客户的研发进程。其他公司则透过专注于特定领域来获得竞争优势，例如专注于高效的下游平台或先进的层析法技术以应对复杂的杂质谱。与设备和一次性用品供应商的技术合作也能透过实现快速製程转移和高效的供应管道来创造竞争优势。

为领导者提供以优先事项为导向、切实可行的建议，以增强流程整合、规模敏捷性、供应链韧性和数数位化，从而获得可持续的竞争优势。

产业领导者应优先考虑一系列切实可行的倡议，使能力投资与新兴技术和监管要求保持一致。首先，推动上游和下游团队之间的跨环节流程整合，以减少交接环节的差异并缩短转移週期。将製程开发科学家、品质专家和放大工程师纳入协作专案团队，可以改善决策，并在下游瓶颈出现之前加以预防。

透明的混合调查方法结合了专家访谈、二手技术资讯和基于场景的检验，确保了可靠的可重复性和实际有效性。

本分析的调查方法结合了定性和定量方法，以确保研究结果的稳健性、可重复性和实用性。主要研究包括对技术领导者、製造企业高管和采购专家进行结构化访谈，以收集他们对营运限制、产能投资和供应商选择标准的第一手观点。这些定性资讯与来自监管指导文件、行业标准和同行评审文献的二级资讯来源进行三角验证，以检验技术论点并整合观察到的趋势。

指导相关人员顺利完成抗体生产转型的策略要务：风险缓解策略和机会管道的简要概述

总而言之，抗体契约製造正经历着由技术创新、监管完善和不断变化的商业性预期所驱动的结构性变革。上游生产效率的提升与下游纯化策略的结合是提高产量和降低转换风险的关键，而关税和贸易因素也日益影响采购和供应链的设计。区域动态的增加更增添了复杂性，需要灵活的布局和统一的品质系统来支援跨区域专案。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧和机器学习整合到抗体生产流程分析中，以提高生产效率
  • 采用灵活且可扩展的一次性反应器系统进行单株抗体生产
  • 实施连续生物製造平台可降低抗体合约生产商的成本并缩短生产週期。
  • 先进的宿主细胞株工程技术可提高单株抗体的高效价和製程一致性。
  • 监管协调倡议旨在促进全球抗体契约製造的核准管道。
  • 生物相似抗体CMC服务的出现满足了市场对高性价比生技药品日益增长的需求。
  • 透过整合数位双胞胎建模和即时监测来优化抗体生产工艺
  • 扩大个人化免疫疗法抗体生产规模，以支持特定癌症和自体免疫疾病的治疗
  • 在抗体合约生产商处实施永续绿色生产实践，以减少对环境的影响
  • 利用高性能筛检平台筛选抗体候选药物，加速开发平臺。

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章：下游抗体契约製造市场

  • 层析法纯化
    • 疏水交互作用层析法
    • 离子交换层析法
    • 蛋白质A层析法
  • 过滤和离心
  • 超过滤和渗滤
  • 上游
    • 反应器运行
    • 细胞株构建
    • 培养基和饲料的製备

第九章 抗体契约製造市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十章：按组别分類的抗体契约製造市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十一章 各国抗体契约製造市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十二章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Lonza Group Ltd
    • Samsung Biologics Co., Ltd
    • 药明生物（香港）有限公司
    • Catalent, Inc.
    • Boehringer Ingelheim International GmbH
    • Fujifilm Diosynth BIoTechnologies US, LLC
    • Merck KGaA
    • AGC Biologics Inc
    • Thermo Fisher Scientific Inc.
    • Rentschler Biopharma SE
Product Code: MRR-742BD517AE6B

The Antibodies Contract Manufacturing Market is projected to grow by USD 42.17 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.04 billion
Estimated Year [2025] USD 20.05 billion
Forecast Year [2032] USD 42.17 billion
CAGR (%) 11.19%

Comprehensive introduction to antibody contract manufacturing landscape emphasizing supply chain complexities operational resilience technological enablers and stakeholder imperatives

The antibody contract manufacturing landscape is experiencing a period of intense operational refinement driven by technological advances, regulatory expectations, and shifting commercial imperatives. This introduction situates the reader in a rapidly professionalizing sector where manufacturers and clients alike prioritize consistent quality, scalable workflows, and reproducible supply chains. As therapeutic modalities diversify and development timelines compress, contract manufacturers are being evaluated not only for unit operations expertise but for their ability to integrate upstream and downstream processes into robust end-to-end solutions that reduce translational risk.

In practice, this means that strategic decisions now extend beyond single process improvements to include platform selection, vendor interoperability, and lifecycle management of biologics. Consequently, stakeholders are placing greater emphasis on cross-functional collaboration, aligning process development teams with quality and regulatory groups early in the program lifecycle to preempt downstream bottlenecks. Furthermore, investment in flexible manufacturing architectures and advanced analytics has become a differentiator that supports faster scale-up, improved yield consistency, and tighter process control.

Looking ahead, the interplay between scientific innovation and operational excellence will determine competitive advantage. Companies that adopt modular production capabilities, embrace quality-by-design principles, and cultivate resilient supply ecosystems will be positioned to meet the accelerating demand for specialized antibody formats. This introduction lays the groundwork for a deeper analysis of systemic shifts, tariff implications, segmentation dynamics, regional nuances, competitive behavior, and actionable guidance for leaders intent on navigating this evolving market environment.

Analysis of transformative operational technological and regulatory shifts that are redefining antibody contract manufacturing models quality expectations and partnership dynamics

The past several years have seen transformative shifts that are recalibrating expectations across antibody contract manufacturing operations. Automation and digitization have migrated from pilot projects to core process control, enabling tighter monitoring of critical quality attributes and delivering data continuity across development and commercial stages. In parallel, single-use technologies and modular facilities have reduced time-to-deploy and increased flexibility, allowing service providers to accommodate diverse client portfolios without extensive retrofitting.

Cell-line engineering and process intensification are raising the bar for upstream productivity, while innovations in chromatography and impurity clearance are reshaping downstream strategies. As a result, the traditional delineation between development and manufacturing partners is blurring; integrated service models that span cell-line development, process transfer, and clinical supply are gaining traction because they reduce handoff risk and accelerate timelines. Moreover, a growing emphasis on digital twins and model-based control is permitting predictive maintenance and process optimization that materially improve batch consistency.

Regulatory authorities have also adapted, placing new emphasis on data integrity, lifecycle management, and comparability for novel modalities. Consequently, contract manufacturers are investing in expandable quality management systems and harmonized documentation to ensure readiness for stricter inspections and cross-border transfers. Meanwhile, strategic sourcing is evolving: supply chain resilience is now as important as unit cost, and companies are diversifying reagent and consumable suppliers to mitigate single-source vulnerabilities. Taken together, these transformative shifts are not incremental; they represent a step change in how manufacturing capacity is organized, governed, and commercialized, and they compel stakeholders to rethink partnerships, capability roadmaps, and long-term investment strategies.

Examination of how new United States tariff policies in 2025 are influencing sourcing decisions supply chain resilience and procurement strategies for antibody manufacturing stakeholders

The introduction of new United States tariff measures in 2025 has introduced an added layer of complexity to procurement and cost management in the antibody contract manufacturing ecosystem. While tariffs do not alter scientific workflows, they influence the economics of sourcing critical reagents, single-use components, and specialized equipment, prompting manufacturers and sponsors to reassess supplier selection criteria and inventory policies. In response, many organizations have revisited their near-term sourcing strategies to prioritize suppliers with diversified manufacturing footprints and established cross-border logistics capabilities.

Consequently, firms are accelerating localization of key supply lines where feasible and negotiating longer-term procurement agreements to stabilize input availability. These changes have also elevated the importance of total landed cost assessments in supplier evaluation frameworks, with procurement teams integrating tariff exposure, customs lead times, and compliance risks into their decision matrices. As a transitional measure, some manufacturers have increased strategic stock levels for critical low-turnover components to buffer against disruption, while others have reconfigured production schedules to align with expected customs clearances and seasonal shipping constraints.

In addition, the tariff environment has intensified due diligence on supply chain transparency, particularly for items sourced through multi-tiered vendors. Contract manufacturers and sponsors are increasingly demanding greater traceability, origin documentation, and contingency planning as part of contractual terms. Collectively, these adjustments reflect a broader shift: geopolitical and trade policy variables now sit alongside quality and regulatory considerations when designing resilient manufacturing strategies, and organizations that proactively incorporate these factors into their planning will be better positioned to maintain continuity and service levels under evolving trade regimes.

Segment-driven insights connecting downstream chromatography modalities and upstream bioprocess elements to capability design operational priorities and process integration choices

A nuanced segmentation analysis reveals how distinct process domains and their subcomponents drive capability requirements and investment priorities across the antibody manufacturing value chain. When viewed through a downstream lens, key operational areas encompass chromatography purification, filtration and centrifugation, and ultrafiltration and diafiltration, each of which imposes specific technical specifications and facility needs. Chromatography purification itself fragments into hydrophobic interaction chromatography, ion exchange chromatography, and Protein A chromatography, and each of these modalities influences resin handling practices, buffer consumption, and single-use compatibility, thereby shaping downstream footprint and operating expenditure profiles.

Upstream activities interconnect tightly with downstream choices and are composed of bioreactor operation, cell line development, and media and feed preparation. Decisions made during cell line development, including clone selection and expression systems, have outsized implications for downstream burden and purification strategy; similarly, bioreactor operation parameters determine impurity profiles and process robustness, which cascade into chromatography load and filtration sequencing. Media and feed preparation further affect process control and consistency, and the selection of feeds compatible with intensified or perfusion-based bioreactors can shift capital and consumables allocation between upstream and downstream units.

Given this segmentation, companies must prioritize interoperability across unit operations and invest in platform technologies that reduce variability at handoffs. In practice, integrated process development that aligns chromatography modalities with expected impurity spectra and upstream productivity yields smoother transfers and accelerates clinical supply readiness. Therefore, segment-level optimization, rather than isolated improvements, delivers disproportionate gains in throughput, quality, and time-to-clinic, and it should guide capability roadmaps and partner selection criteria.

Regional analysis highlighting how strategic footprints across the Americas Europe Middle East & Africa and Asia-Pacific shape regulatory compliance capacity planning and supply resilience

Regional dynamics materially influence strategic priorities for contract manufacturers and sponsors, and recognizing the nuanced differences among the Americas, Europe Middle East & Africa, and Asia-Pacific regions is essential for effective capacity planning and regulatory navigation. In the Americas, commercial-scale capacity and proximity to major biopharma hubs often favor rapid program transition from development to clinic, while regulatory authorities emphasize robust documentation and post-approval surveillance that can influence manufacturing continuity planning. Conversely, Europe Middle East & Africa exhibits a more fragmented regulatory mosaic, which necessitates flexible quality systems and localized market expertise to manage multi-jurisdictional releases and inspections.

Asia-Pacific presents a different set of considerations, including rapidly expanding local manufacturing capabilities, varying regulatory maturity across markets, and cost-competitive supply chains for consumables and support services. In response, many global and regional contract manufacturers are establishing hybrid footprints that combine strategic sites in each of these regions to balance speed-to-market, cost-efficiency, and risk mitigation. Moreover, cross-regional partnerships and tolling arrangements have emerged as pragmatic solutions to address capacity fluctuations and national regulatory preferences. As cross-border supply chains become increasingly sophisticated, stakeholders are investing in regional supply chain orchestration capabilities and harmonized quality management to reduce friction in product transfers across these diverse geographies.

Ultimately, regional strategy is no longer solely about cost, but about positioning firms to respond to regulatory expectations, secure talent pools, and localize critical inputs. By aligning facility capabilities and service offerings with the specific operational and regulatory realities of the Americas, Europe Middle East & Africa, and Asia-Pacific, manufacturers and sponsors can optimize program execution and shorten timelines for global development and commercialization.

Competitive landscape synthesis describing how capability integration operational excellence and strategic partnerships determine differentiation and service reliability

Competitive positioning among key companies in the antibody contract manufacturing space reflects a blend of technical depth, integrated service offerings, and strategic partnerships. Market leaders differentiate by offering holistic solutions spanning cell-line development, process optimization, scale-up, and commercialization support, thereby reducing handoff risk and accelerating client timelines. Others achieve differentiation through niche specialization, for example by focusing on high-efficiency downstream platforms or advanced chromatography capabilities that address challenging impurity profiles. Technology partnerships with instrument and single-use suppliers also create competitive advantages by enabling faster process transfers and validated supply channels.

In addition to technical capabilities, operational excellence is a significant discriminator. Firms that invest in robust quality management systems, harmonized documentation practices, and transparent regulatory interactions gain trust among sophisticated sponsors whose programs demand predictable outcomes. Strategic alliances and networked manufacturing models further expand service reach and mitigate capacity shortfalls, while mergers and capacity-sharing agreements have become common methods to rapidly increase geographic coverage and expand modality expertise. Importantly, client selection criteria increasingly factor in a provider's ability to deliver end-to-end traceability, data continuity, and a documented track record of successful tech transfers.

Consequently, companies that combine process innovation, operational rigor, and flexible commercial models are best positioned to capture demanding partnerships. For procurement teams and investors, assessing the strength of a provider's integration across development and manufacturing, rather than isolated capabilities, yields a clearer view of long-term service reliability and strategic fit.

Priority oriented and actionable recommendations for leaders to enhance process integration scale agility supply resilience and digitalization for sustainable competitive advantage

Industry leaders should prioritize a set of actionable initiatives that align capacity investments with emerging technological and regulatory imperatives. First, elevate cross-disciplinary process integration between upstream and downstream teams to reduce handoff variability and shorten transfer cycles. Embedding process development scientists, quality experts, and scale-up engineers in joint program teams improves decision-making and preempts downstream bottlenecks, which accelerates development velocity while preserving product quality.

Second, adopt flexible manufacturing designs and modular facility approaches that support rapid repurposing and scale adjustments. By combining single-use technologies with modular cleanroom architectures, organizations can increase responsiveness to varied client demands without incurring the long lead times associated with traditional capital projects. Third, strengthen supply chain resilience by diversifying sourcing across geographies and qualifying multiple suppliers for critical reagents and components; this reduces exposure to tariff shifts and logistics disruptions. Fourth, invest in digital infrastructure that supports real-time analytics, process modeling, and electronic batch records to improve traceability and facilitate regulatory submissions.

Finally, pursue strategic partnerships that extend capabilities rather than replicate them. Alliances that fill gaps in chromatography expertise, cell-line engineering, or regional regulatory know-how can provide near-term capacity and skill enhancements while preserving capital flexibility. Implementing these recommendations will allow organizations to improve operational agility, reduce program risk, and maintain competitive service offerings in a landscape defined by rapid scientific and commercial evolution.

Transparent mixed methodologies combining primary expert interviews secondary technical sources and scenario based validation to ensure robust reproducibility and practical relevance

The research methodology underpinning this analysis combines qualitative and quantitative approaches designed to ensure robustness, reproducibility, and practical relevance. Primary research included structured interviews with technical leaders, manufacturing executives, and procurement specialists to capture first-hand perspectives on operational constraints, capability investments, and supplier selection criteria. These qualitative inputs were triangulated with secondary source material drawn from regulatory guidance documents, industry standards, and peer-reviewed literature to validate technical assertions and to contextualize observed trends.

Analytical workflows employed process mapping to identify critical handoff points between upstream and downstream activities, and scenario analysis to evaluate responses to supply chain shocks and tariff changes. Validation rounds with subject matter experts refined interpretations and ensured that recommended actions reflect operational realities. Where appropriate, cross-case comparisons were used to surface best practices and to highlight variations in regional regulatory approaches and facility architectures. Throughout, emphasis was placed on transparent documentation of assumptions and data provenance so that readers can adapt the methodology to their internal audit or compliance frameworks.

This mixed-methods approach ensures that conclusions are grounded in practitioner experience and supported by technical literature, while remaining adaptable to specific program-level questions and operational constraints.

Concise synthesis of strategic imperatives risk mitigation tactics and opportunity pathways to guide stakeholders through antibody manufacturing transitions

In sum, antibody contract manufacturing is undergoing a period of structural evolution driven by technological innovation, regulatory refinement, and shifting commercial expectations. The interplay between upstream productivity enhancements and downstream purification strategies is central to improving throughput and reducing translational risk, while tariff and trade considerations increasingly influence procurement and supply chain design. Regional dynamics add another layer of complexity that requires adaptable footprints and harmonized quality systems to support multi-jurisdictional programs.

Organizations that integrate process development with manufacturing, invest in flexible and digital-enabled facilities, and pursue targeted partnerships will secure operational advantages and mitigate exposure to external shocks. By focusing on interoperability across unit operations, strengthening supply chain transparency, and aligning regional strategies with regulatory realities, stakeholders can better navigate the evolving environment and deliver reliable outcomes for complex antibody modalities. The concluding synthesis underscores the need for a proactive, integrated approach to capability development and commercial strategy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence and machine learning in antibody process analytics to enhance manufacturing efficiency
  • 5.2. Adoption of single use bioreactor systems for flexible and scalable monoclonal antibody production
  • 5.3. Implementation of continuous biomanufacturing platforms to reduce costs and accelerate antibody CMO timelines
  • 5.4. Advanced host cell line engineering drives higher monoclonal antibody titers and process consistency
  • 5.5. Regulatory harmonization initiatives facilitating global antibody contract manufacturing approval pathways
  • 5.6. Emergence of biosimilar antibody CMC service offerings to meet rising demand for cost effective biologics
  • 5.7. Integration of digital twin modeling and real time monitoring to optimize antibody manufacturing processes
  • 5.8. Expansion of personalized immunotherapy antibody manufacturing to support niche oncology and autoimmune treatments
  • 5.9. Implementation of sustainable green manufacturing practices to reduce environmental impact in antibody CMOs
  • 5.10. Adoption of high throughput screening platforms to accelerate antibody candidate selection and development pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibodies Contract Manufacturing Market, by Downstream

  • 8.1. Chromatography Purification
    • 8.1.1. Hydrophobic Interaction Chromatography
    • 8.1.2. Ion Exchange Chromatography
    • 8.1.3. Protein A Chromatography
  • 8.2. Filtration And Centrifugation
  • 8.3. Ultrafiltration And Diafiltration
  • 8.4. Upstream
    • 8.4.1. Bioreactor Operation
    • 8.4.2. Cell Line Development
    • 8.4.3. Media And Feed Preparation

9. Antibodies Contract Manufacturing Market, by Region

  • 9.1. Americas
    • 9.1.1. North America
    • 9.1.2. Latin America
  • 9.2. Europe, Middle East & Africa
    • 9.2.1. Europe
    • 9.2.2. Middle East
    • 9.2.3. Africa
  • 9.3. Asia-Pacific

10. Antibodies Contract Manufacturing Market, by Group

  • 10.1. ASEAN
  • 10.2. GCC
  • 10.3. European Union
  • 10.4. BRICS
  • 10.5. G7
  • 10.6. NATO

11. Antibodies Contract Manufacturing Market, by Country

  • 11.1. United States
  • 11.2. Canada
  • 11.3. Mexico
  • 11.4. Brazil
  • 11.5. United Kingdom
  • 11.6. Germany
  • 11.7. France
  • 11.8. Russia
  • 11.9. Italy
  • 11.10. Spain
  • 11.11. China
  • 11.12. India
  • 11.13. Japan
  • 11.14. Australia
  • 11.15. South Korea

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Analysis
    • 12.3.1. Lonza Group Ltd
    • 12.3.2. Samsung Biologics Co., Ltd
    • 12.3.3. WuXi Biologics (Hong Kong) Co., Ltd
    • 12.3.4. Catalent, Inc.
    • 12.3.5. Boehringer Ingelheim International GmbH
    • 12.3.6. Fujifilm Diosynth Biotechnologies US, LLC
    • 12.3.7. Merck KGaA
    • 12.3.8. AGC Biologics Inc
    • 12.3.9. Thermo Fisher Scientific Inc.
    • 12.3.10. Rentschler Biopharma SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 118. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 124. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 125. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 126. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 127. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 128. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 142. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 143. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 144. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 145. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 146. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 147. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 150. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 151. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 154. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 163. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 166. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 167. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 168. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 169. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 170. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 171. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 174. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 175. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 176. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 177. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 178. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 179. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 182. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 183. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 186. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 195. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 197. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 199. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 201. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 203. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 205. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 207. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 209. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 211. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 219. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 221. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 223. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 225. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 226. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 227. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 228. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 229. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 230. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 231. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 232. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 233. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 234. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 235. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 236. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 237. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 239. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 241. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 243. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 245. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 247. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 249. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 250. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 251. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 252. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 253. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 254. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 255. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 256. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 257. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 258. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 259. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 260. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 261. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 262. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 263. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 264. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 265. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 266. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 267. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 268. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 270. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 272. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 273. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 274. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 275. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 276. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 277. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 278. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 279. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 280. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024